BIOGEN INC. Increase (Decrease) in Other Operating Assets
BIOGEN INC. (BIIB) reported Increase (Decrease) in Other Operating Assets of $119.10 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2019-02-06
- BIOGEN INC. increase (decrease) in other operating assets for the quarter ending 2011-12-31 was $12.13M.
- BIOGEN INC. increase (decrease) in other operating assets for the quarter ending 2011-09-30 was $761.00K, a 97.08% decline year-over-year.
- BIOGEN INC. increase (decrease) in other operating assets for the quarter ending 2011-06-30 was $13.20M.
- BIOGEN INC. increase (decrease) in other operating assets for the quarter ending 2011-03-31 was $17.15M, a 27.42% increase year-over-year.
- BIOGEN INC. increase (decrease) in other operating assets for fiscal 2018 was $119.10M, a 55.48% increase from fiscal 2017.
- BIOGEN INC. increase (decrease) in other operating assets for fiscal 2017 was $76.60M.
- BIOGEN INC. increase (decrease) in other operating assets for fiscal 2016 was -$59.10M, a 146.54% decline from fiscal 2015.
- BIOGEN INC. increase (decrease) in other operating assets for fiscal 2015 was $127.00M, a 16.84% increase from fiscal 2014.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 3 month as first filed | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 6 month as first filed | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 9 month as first filed | Increase (Decrease) in Other Operating Assets 12 month | Increase (Decrease) in Other Operating Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | $119.10M 10-K · filed 2019-02-06 | |||||||
| 2017-12-31 | $76.60M 10-K · filed 2019-02-06 | |||||||
| 2016-12-31 | -$59.10M 10-K · filed 2019-02-06 | |||||||
| 2015-12-31 | $127.00M 10-K · filed 2018-02-01 | $156.60M 10-K · filed 2016-02-03 | ||||||
| 2014-12-31 | $108.70M 10-K · filed 2017-02-02 | $94.51M 10-K · filed 2015-02-04 | ||||||
| 2013-12-31 | $160.20M 10-K · filed 2016-02-03 | $160.19M 10-K · filed 2014-02-06 | ||||||
| 2012-12-31 | $27.35M 10-K · filed 2015-02-04 | |||||||
| 2011-12-31 | $12.13M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $12.89M derived: sum of 2 quarters · filed 2014-02-06 | $26.09M derived: sum of 3 quarters · filed 2014-02-06 | $43.24M 10-K · filed 2014-02-06 | ||||
| 2011-09-30 | $761.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $13.96M derived: sum of 2 quarters · filed 2011-10-28 | $31.11M 10-Q · filed 2011-10-28 | $21.26M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-06-30 | $13.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $30.35M 10-Q · filed 2011-07-26 | $20.50M derived: sum of 3 quarters · filed 2013-02-05 | $46.58M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-03-31 | $17.15M 10-Q · filed 2011-04-21 | $7.30M derived: sum of 2 quarters · filed 2013-02-05 | $33.38M derived: sum of 3 quarters · filed 2013-02-05 | $16.27M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2010-12-31 | -$9.85M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $16.22M derived: sum of 2 quarters · filed 2013-02-05 | -$879.00K derived: sum of 3 quarters · filed 2013-02-05 | $12.58M 10-K · filed 2013-02-05 | ||||
| 2010-09-30 | $26.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $8.97M derived: sum of 2 quarters · filed 2011-10-28 | $22.43M 10-Q · filed 2011-10-28 | $8.72M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-06-30 | -$17.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | -$3.64M 10-Q · filed 2011-07-26 | -$17.35M derived: sum of 3 quarters · filed 2012-02-03 | -$31.45M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-03-31 | $13.46M 10-Q · filed 2011-04-21 | -$13.46M 10-Q · filed 2010-04-20 | -$253.00K derived: sum of 2 quarters · filed 2012-02-03 | -$14.35M derived: sum of 3 quarters · filed 2012-02-03 | $5.46M derived: sum of 4 quarters · filed 2012-02-03 | |||
| 2009-12-31 | -$13.72M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | -$27.81M derived: sum of 2 quarters · filed 2012-02-03 | -$8.01M derived: sum of 3 quarters · filed 2012-02-03 | -$22.27M 10-K · filed 2012-02-03 | $22.27M 10-K · filed 2010-02-09 | |||
| 2009-09-30 | -$14.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $5.71M derived: sum of 2 quarters · filed 2010-10-26 | -$8.55M 10-Q · filed 2010-10-26 | $8.55M 10-Q · filed 2009-10-21 | -$37.16M derived: sum of 4 quarters · filed 2011-02-04 | |||
| 2009-06-30 | $19.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $5.54M 10-Q · filed 2010-07-20 | -$5.54M 10-Q · filed 2009-07-17 | -$23.07M derived: sum of 3 quarters · filed 2011-02-04 | $9.25M derived: sum of 4 quarters · filed 2011-02-04 | |||
| 2009-03-31 | -$14.26M 10-Q · filed 2010-04-20 | -$42.87M derived: sum of 2 quarters · filed 2011-02-04 | -$10.55M derived: sum of 3 quarters · filed 2011-02-04 | |||||
| 2008-12-31 | -$28.61M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $3.72M derived: sum of 2 quarters · filed 2011-02-04 | -$3.71M 10-K · filed 2011-02-04 | $3.71M 10-K · filed 2010-02-09 | ||||
| 2008-09-30 | $32.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $24.90M 10-Q · filed 2009-10-21 | ||||||
| 2008-06-30 | -$7.43M 10-Q · filed 2009-07-17 | |||||||
| 2007-12-31 | $238.00K 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |